Your browser doesn't support javascript.
loading
Efficacy and Safety of Bleselumab in Preventing the Recurrence of Primary Focal Segmental Glomerulosclerosis in Kidney Transplant Recipients: A Phase 2a, Randomized, Multicenter Study.
Shoji, Jun; Goggins, William C; Wellen, Jason R; Cunningham, Patrick N; Johnston, Olwyn; Chang, Shirley S; Solez, Kim; Santos, Vicki; Larson, Tami J; Takeuchi, Masahiro; Wang, Xuegong.
Afiliación
  • Shoji J; Division of Transplant Nephrology, University of California San Francisco, San Francisco, CA.
  • Goggins WC; Division of Transplant Surgery, Department of Surgery, Indiana University School of Medicine, Indianapolis, IN.
  • Wellen JR; Division of Transplantation, Department of Surgery, Washington University in St Louis, St Louis, MO.
  • Cunningham PN; Section of Nephrology, Department of Medicine, University of Chicago, Chicago, IL.
  • Johnston O; Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Chang SS; Division of Nephrology, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Erie County Medical Center, Buffalo, NY.
  • Solez K; Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada.
  • Santos V; Astellas Pharma Global Development Inc, Northbrook, IL.
  • Larson TJ; Astellas Pharma Global Development Inc, Northbrook, IL.
  • Takeuchi M; Astellas Pharma Global Development Inc, Northbrook, IL.
  • Wang X; Astellas Pharma Global Development Inc, Northbrook, IL.
Transplantation ; 108(8): 1782-1792, 2024 Aug 01.
Article en En | MEDLINE | ID: mdl-39042770
ABSTRACT

BACKGROUND:

Focal segmental glomerulosclerosis (FSGS) is a common cause of end-stage kidney disease and frequently recurs after kidney transplantation. Recurrent FSGS (rFSGS) is associated with poor allograft and patient outcomes. Bleselumab, a fully human immunoglobulin G4 anti-CD40 antagonistic monoclonal antibody, disrupts CD40-related processes in FSGS, potentially preventing rFSGS.

METHODS:

A phase 2a, randomized, multicenter, open-label study of adult recipients (aged ≥18 y) of a living or deceased donor kidney transplant with a history of biopsy-proven primary FSGS. The study assessed the efficacy of bleselumab combined with tacrolimus and corticosteroids as maintenance immunosuppression in the prevention of rFSGS >12 mo posttransplantation, versus standard of care (SOC) comprising tacrolimus, mycophenolate mofetil, and corticosteroids. All patients received basiliximab induction. The primary endpoint was rFSGS, defined as proteinuria (protein-creatinine ratio ≥3.0 g/g) with death, graft loss, or loss to follow-up imputed as rFSGS, through 3 mo posttransplant.

RESULTS:

Sixty-three patients were followed for 12 mo posttransplantation. Relative decrease in rFSGS occurrence through 3 mo with bleselumab versus SOC was 40.7% (95% confidence interval, -89.8 to 26.8; P = 0.37; absolute decrease 12.7% [95% confidence interval, -34.5 to 9.0]). Central-blinded biopsy review found relative (absolute) decreases in rFSGS of 10.9% (3.9%), 17.0% (6.2%), and 20.5% (7.5%) at 3, 6, and 12 mo posttransplant, respectively; these differences were not statistically significant. Adverse events were similar for both treatments. No deaths occurred during the study.

CONCLUSIONS:

In at-risk kidney transplant recipients, bleselumab numerically reduced proteinuria occurrence versus SOC, but no notable difference in occurrence of biopsy-proven rFSGS was observed.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Recurrencia / Glomeruloesclerosis Focal y Segmentaria / Trasplante de Riñón / Anticuerpos Monoclonales Humanizados / Inmunosupresores Idioma: En Revista: Transplantation Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Recurrencia / Glomeruloesclerosis Focal y Segmentaria / Trasplante de Riñón / Anticuerpos Monoclonales Humanizados / Inmunosupresores Idioma: En Revista: Transplantation Año: 2024 Tipo del documento: Article